Skip to Main Content

Press Releases

Press Release

Innovative Synthetic DNA-based Cancer Immunotherapy Approach Shows Tumor-clearing Ability in Preclinical Models

PHILADELPHIA — (April 18, 2019) — Wistar scientists have developed a novel synthetic DNA approach for patient-specific production of cancer-targeting molecules called bispecific T cell engagers. DNA-encoded bispecific T cell engagers (dBiTEs) designed against the HER2 protein were tested in preclinical models of ovarian cancer and induced tumor regression, demonstrating the potential of this novel approach for immunotherapy. Study results were published online in JCI Insights